-- Telix Pharmaceuticals（ASX：TLX）周三发布声明称，其针对复发性胶质母细胞瘤的关键性Ipax BrIGHT试验中，首例患者已接受候选药物TLX101-Tx（碘-131-碘法兰）的给药。 该公司表示，该研究旨在评估TLX101-Tx联合化疗与单独化疗相比的安全性和有效性。研究将招募首次复发且经影像学确诊的复发性胶质母细胞瘤患者。 该研究已获得澳大利亚、奥地利、比利时和荷兰的监管部门批准，该公司正在寻求更多地区的批准。 Telix Pharmaceuticals的股价在周三的交易中下跌超过6%。
Related Articles
Asia
Changhong's Attributable Profit Plummets 72% in Q1
Sichuan Changhong Electric's (SHA:600839) attributable profit fell 72% to 98.5 million yuan in the first quarter from 345.5 million yuan in the year-ago period, according to a Saturday filing with the Shanghai bourse.Earnings per share at the consumer electronics manufacturer decreased 71% to 0.0214 yuan from 0.0748 yuan in the prior-year period.Operating income edged up 1.6% year over year to 27.3 billion yuan from 26.8 billion yuan.Shares decreased 5% during morning trading on Monday.
$SHA:600839
Asia
China Energy Engineering Logs 29% Decrease in Q1 2026 Contract Value
China Energy Engineering (SHA:601868, HKG:3996) logged a 29% year-on-year decrease in total new contract value in the first quarter of 2026, according to a Hong Kong bourse filing Friday.Hong Kong-listed shares of the construction firm fell over 2% in Monday late morning trade.The value of new contracts reached 276.2 billion yuan during the quarter, including 184.81 billion yuan from domestic sources and 91.39 billion yuan from overseas.
$HKG:3996$SHA:601868
Asia
Shanghai Zhangjiang Hi-Tech Park Development's Attributable Profit Slides 72% in Q1; Shares Fall 3%
Shanghai Zhangjiang Hi-Tech Park Development's (SHA:600895) attributable profit fell 72% to 83.5 million yuan in the first quarter from 294.5 million yuan in the year-ago period, according to a Saturday filing with the Shanghai bourse.Earnings per share at the real estate developer decreased 72% to 0.05 yuan from 0.18 yuan in the prior-year period.Operating income declined 31% year over year to 838 million yuan from 1.22 biliion yuan.Shares decreased 3% during the midday trade on Monday.
$SHA:600895